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Determinants of diagnostic performance of 18F-FDG PET/CT
in patients with fever of unknown origin
Ashoka M.V. Pereiraa,*, Lars Husmannb,*, Bert-Ram Sahb,
Edouard Battegaya,d,e and Daniel Franzenc
Objectives There is uncertainty about patient selection
and the adequate timing at which fluorine-18
fluorodeoxyglucose (18F-FDG) PET/computed tomography
(CT) is indicated in the diagnostic work-up of fever of
unknown origin (FUO). The aim of this study was to
determine the diagnostic performance of 18F-FDG PET/CT
in patients with FUO.
Methods All consecutive patients who underwent 18F-FDG
PET/CT at the University Hospital Zurich because of FUO
between 2006 and 2012 were included in this retrospective,
observational study.
Results A total of 76 patients [70% men, median
(interquartile range) age 60 (47–67) years] were included.
18F-FDG PET/CT showed characteristically increased
18F-FDG activity in 56 patients (74%), leading to
confirmation of or change in the suspected cause of FUO in
57 and 17%, respectively. The final diagnosis after 18F-FDG
PET/CT included infection (21%), malignancy (22%),
noninfectious inflammatory disease (12%), others (5%), or
an unknown cause (40%). The success rate, sensitivity, and
specificity of 18F-FDG PET/CT were 60, 77, and 31%,
respectively. Sensitivity was highest in patients with
suspected malignancy (100%, 95% confidence interval
79–100%). Diagnostic performance was independent of the
investigated variables other than suspected infection as a
cause of FUO (odds ratio 0.1, 95% confidence interval
0.01–0.8, P= 0.033).
Conclusion The diagnostic performance of 18F-FDG
PET/CT was significantly higher in patients with suspected
malignancy causing a FUO compared with suspected
infection or noninfectious inflammatory disease. However,
it was independent of the baseline characteristics and
duration of fever. This supports the recommendation to
perform 18F-FDG PET/CT early in the diagnostic work-up of
FUO, which may shorten disease duration and lower health
costs, particularly when infection or malignancy is
suspected. Nucl Med Commun 37:57–65 Copyright © 2015
Wolters Kluwer Health, Inc. All rights reserved.
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Background
Fever of unknown origin (FUO) was originally defined in
1961 by Petersdorf and Beeson [1] as an illness with recur-
rent fever of more than 38.3°C lasting 3 weeks or more, and
without a diagnosis after 1 week of detailed clinical inves-
tigation. To satisfy modern outpatient-based medicine,
Durack and Street [2] suggested shortening the duration of
investigations to three inpatient days or three outpatient
visits. However, as investigations in outpatient and inpatient
settings are difficult to compare, different causes of FUO
would be found. Instead of using arbitrary quantitative time
criteria, a quantitative criterion of obligatory investigations
was implemented in the definition [3]. Since then, FUO is
defined as follows [4]: (a) temperature of at least 38.3°C on
at least two occasions, (b) duration of illness of at least
3 weeks or multiple febrile episodes in at least 3 weeks, (c)
not immunocompromised, (d) diagnosis uncertain despite
thorough assessment of history, physical examination, and
the following investigations: erythrocyte sedimentation rate
or C-reactive protein, hemoglobin, platelet count, leukocyte
count and differentiation, electrolytes, creatinine, total pro-
tein, protein electrophoresis, alkaline phosphatase, aspartate
aminotransferase, alanine aminotransferase, lactate dehy-
drogenase, creatine kinase, antinuclear antibodies, rheuma-
toid factor, microscopic urinalysis, ferritin, three blood
cultures, urine culture, chest radiography, abdominal ultra-
sonography, and tuberculin skin test.
The cause of FUO is mainly classified into four cate-
gories including infection, malignancy, noninfectious
inflammatory disease (NIID), and unknown cause [5–7].
Early identification and precise localization of the cause
of FUO are crucial for the appropriate treatment of some
distinct causes. However, despite advances in diagnostic
techniques, it remains a clinical challenge to identify the
etiology of FUO.
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PET using fluorine-18 fluorodeoxyglucose (18F-FDG) is
a well-established imaging tool for detection of malig-
nancy [8–12]. Inflammatory cells and tumor cells share a
similar molecular basis of 18F-FDG uptake, for example
overexpression of glucose transporter (GLUT-1 and
GLUT-3) and glycolytic enzymes. Studies have indi-
cated that 18F-FDG PET is a valuable imaging technique
for the diagnosis of infection and inflammation, and
is a promising tool in the diagnostic work-up of FUO
[5,13–16]. Although the first combined PET/computed
tomography (CT) system became operational in 2001
already [17], only a small number of studies have asses-
sed 18F-FDG PET/CT in patients with FUO [18–27].
Furthermore, it is not clear when to perform an 18F-FDG
PET/CT for diagnostic work-up of FUO. The aim of the
present study was to determine the diagnostic perfor-
mance of 18F-FDG PET/CT in patients who present
themselves with FUO, and to define patient character-
istics in which an 18F-FDG PET/CT makes a significant
contribution toward determining the cause.
Methods
Patients
All consecutive inpatients and outpatients who under-
went 18F-FDG PET/CT at the University Hospital
Zurich because of FUO between 1 January 2006 and 30
June 2012 were included in this retrospective, observa-
tional study. Eligible patients were identified in the
radiology information system using various subject
headings including ‘FUO’, ‘fever of known origin’,
‘unexplained fever’, and ‘fever of unknown cause or
reason’. Thereafter, on the basis of the patient records, all
adults were included who fulfilled a modified definition
of FUO including (a) temperature of at least 38.3°C on at
least two occasions and (b) duration of illness of at least
3 weeks or multiple febrile episodes in at least 3 weeks
[1,4]. The patients were divided into four categories of
FUO according to the publications of Durack and Street
[2]: classical, nosocomial, HIV-associated, and immuno-
deficiency (neutropenia) as we did not exclude immu-
nocompromised patients from the study.
Written informed consent was obtained from all patients.
The study was approved by the Ethics Committee of the
Canton of Zurich, Switzerland (KEK-ZH 2012–0308),
and is registered at http://www.clinicaltrials.gov (Identifier:
NCT01840891).
18F-FDG PET/CT imaging
Patients fasted for at least 4 h and had no insulin injec-
tions 4 h before 18F-FDG administration. Body weight,
height, and blood glucose level were measured before
injection of 18F-FDG. In nondiabetic patients, blood
glucose levels less than 8 mmol/l were accepted for
imaging and in diabetic patients blood glucose levels less
than 12 mmol/l were accepted for imaging. After an
intravenous injection of body weight-adapted 18F-FDG
(18F-FDG dosage of 5MBq/kg body weight), patients
rested for a standardized uptake time of 60 min.
Data were acquired with the patient in the supine posi-
tion with the arms overhead. Low-dose CT for attenua-
tion correction was acquired from the mid-thigh to the
vertex of the skull with the following scan parameters:
tube voltage, 140 kVp; tube current time product,
10–80mAs/slice; pitch of 1.4; collimation, 64× 0.625 mm;
rotation time, 0.5 ms; and field of view 50 cm. Directly
after CT data acquisition, PET data were acquired using
the 3D mode with a fixed scan duration of 2 min per bed
position and a field of view of 157 mm. Emission data
were corrected for randoms, dead time, scatter, and
attenuation. CT data for attenuation correction and ana-
tomical referencing were reconstructed with a slice
thickness of 3.75 mm and an increment of 3.0 mm using
a filtered back reconstruction algorithm. Attenuation-
corrected axial PET images were reconstructed using a
standard iterative ordered subset expectation maximiza-
tion 3D algorithm (matrix size, 256× 256, Fourier rebin-
ning, 3D ordered subset expectation maximization with
eight iterations, 16 subsets). Scans were performed using
an integrated PET/CT system (Discovery VCT; GE
Healthcare, Milwaukee, Wisconsin, USA).
Table 1 Patient and fever characteristics before 18F-FDG PET/CT
Characteristic Value
Male sex [n (%)] 53 (69.7)
Age (years) [median (IQR)] 60 (47–67)
Pre-existing medical conditions [n (%)]
Malignancy 23 (30.3)
HIV 4 (5.2)
Solid organ transplantation 8 (10.5)
Travel to tropical regions within 6 months [n
(%)]
5 (6.5)
Addiction to illicit drugs [n (%)] 7 (9.2)
Grouping of FUO [n (%)]
Classical FUO 56 (73.3)
HIV-associated 4 (5.2)
Neutropenia 1 (0.8)
Symptoms [n (%)]
Constitutional (night sweats, loss of weight) 19 (25.0)
Respiratory 25 (32.9)
Abdominal 27 (35.5)
Arthralgia 16 (21.1)
Myalgia 24 (31.6)
Cephalgia 12 (15.8)
No concurrent symptoms 16 (21.1)
Fever [n (%)]
Continuous 20 (26.3)
Periodic or intermittent 56 (73.7)
Duration (days) 57 (30–182),
range: 21–1460
Medication [n (%)]
Corticosteroid 25 (32.9)
Immunosuppressant (other than
corticosteroids)
12 (15.8)
Antibiotic 46 (60.5)
Chemotherapy 5 (6.6)
NSAID 13 (17.1)
Antipyretic 23 (30.3)
CT, computed tomography; 18F-FDG, fluorine-18 fluorodeoxyglucose; FUO, fever
of unknown origin; IQR, interquartile range.
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Interpretation and analysis of 18F-FDG PET/CT
The nuclear physician reading the 18F-FDG PET/CT at
the Department of Nuclear Medicine had knowledge of
the patient’s clinical history and results of previous ima-
ging studies. Any 18F-FDG uptake was considered
pathologic or positive when intensity was higher than
that in surrounding tissues and it was not localized in an
area with a physiologic biodistribution of the radio-
pharmaceutical. A negative 18F-FDG PET/CT finding
was present when tracer activity was only detectable in
areas of physiologic uptake of 18F-FDG and when no
sites of increased uptake were visible. In line with pre-
vious studies [3,22–24], the diagnostic performance was
defined as follows: a true positive finding was considered
when 18F-FDG PET/CT showed a pathological tracer
uptake as the cause of FUO, which was confirmed by
further investigations (biopsy) or clinical follow-up. A
pathological 18F-FDG uptake, which was not confirmed
as the cause of FUO, was considered false positive. A
negative 18F-FDG PET/CT finding was considered true
negative when no cause of FUO was found despite
extensive diagnostic work-up and a follow-up of
3 months. It was considered false negative when there
was evidence of an infection, NIID, or malignancy as a
cause of FUO despite a normal 18F-FDG PET/CT
finding. Furthermore, the success rate of 18F-FDG PET/
CT was defined as ‘helpful’ or ‘noncontributory’
according to their effect on the determination of the final
diagnosis (cause of FUO).
Outcome measures
The primary outcome was to determine the success rate
and diagnostic performance of 18F-FDG PET/CT in
patients presenting with FUO. The secondary outcome
was to investigate possible determinants of a helpful
18F-FDG PET/CT considering various variables [sex,
age, duration, and characteristics of the fever (inter-
mittent vs. continuous FUO), constitutional symptoms,
inflammatory markers, FUO classification according to
Durack and Street [2], and suspected cause of FUO].
The suspected and final diagnoses had been made by
study-independent, treating physicians. According to
this, the diagnoses were classified into the following
groups: infection, NIID, malignancy, or indefinite/
unknown as proposed elsewhere [5–7].
Statistical analysis
All statistical analyses were carried out using IBM SPSS
Statistics for Windows, version 22 (IBM Corporation,
Armonk, New York, USA). Continuous data are reported
Fig. 1
Results from a 73-year-old patient presenting with fever. PET/CT provided a diagnosis of pericarditis that responded immediately to antibiotic
treatment. (a) Maximum intensity projection 60min after an injection of 352MBq 18F-FDG. (b) Axial slice of fused PET/CT images, showing
metabolically active pericarditis. (c) Axial slice of the corresponding PET image. CT, computed tomography; 18F-FDG, fluorine-18 fluorodeoxyglucose.
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as median [interquartile range (IQR)] and categorical data
are reported in absolute counts (percentages). Helpful
and noncontributory 18F-FDG PET/CT findings were
compared using the χ2-test (categorical variables) or
Student’s t-test (continuous variables). A univariable
logistic regression model was first used to assess the
individual effect of each covariate on the success rate of
18F-FDG PET/CT. Variables with a P-value equal to or
less than 0.1 in the univariable analysis were entered into
the multivariable regression analysis. P-values of all out-
comes were two-sided; a value less than 0.05 was con-
sidered to indicate statistical significance. For sensitivity,
specificity, positive predictive value, negative predictive
value, positive likelihood ratio, and negative likelihood
ratio, the 95% confidence intervals were calculated.
Results
Of 176 patients who were identified using one of the
search terms, 100 had to be excluded because of various
reasons: definition of FUO not fulfilled (n= 82), no
follow-up data (n= 8), missing informed consent (n= 8),
and incomplete data (n= 2). A total of 76 patients [69.7%
men, median age 60 (47–67) years] were included in this
study (Table 1 and Figs 1–4). Pre-existing risk factors for
FUO were present in 46.1% (malignancy, HIV infection,
or solid organ transplantation). The majority of patients
were classified as having ‘classical FUO,’ 73.7%. The
most prevalent concurrent symptom was gastrointestinal
discomfort (pain or nausea) in 35.5%. In 21.1%, fever was
the only symptom. The fever was intermittent or periodic
in 73.7% of patients, whereas only 26.3% had continuous
fever. Its median (IQR) duration before 18F-FDG
PET/CT was 57 (30–182) days, with a median (IQR)
maximum body temperature of 39.1 (38.8–40.0)°C.
Laboratory investigations before 18F-FDG PET/CT are
listed in Table 2. The median values of inflammation
parameters were moderately elevated, and patients were
anemic, whereas median leukocytes and procalcitonin
values were within normal ranges. In most patients, a CT
of the chest (n= 54, 71%) and/or the abdomen (n= 57,
75%) had been carried out before the 18F-FDG PET/CT,
without conclusive results. Echocardiography to rule out
endocarditis had been performed in 45 patients (42%).
On the basis of the examinations performed before
18F-FDG PET/CT, the suspected cause of FUO was
infection (n= 37), malignancy (n= 22), NIID (n= 12), or
unknown (n= 5).
18F-FDG PET/CT indicated pathological 18F-FDG
activity in 56 patients (73.7%), leading to confirmation of
Fig. 2
Results from a 42-year-old patient presenting with fever. PET/CT showed Hodgkin’s disease with bone marrow manifestation only. (a) Maximum
intensity projection 60min after an injection of 327MBq 18F-FDG. (b) Axial slice of fused PET/CT images, showing multiple metabolically active bone
marrow manifestations. (c) Axial slice of the corresponding PET image. CT, computed tomography; 18F-FDG, fluorine-18 fluorodeoxyglucose.
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the suspected cause of FUO in 56.6% (43/76) of the cases
(Fig. 4). In 17.1% (13/76), there was an 18F-FDG PET/CT
finding, which was incongruent with the suspected cause
and led to an alternative diagnosis (Fig. 4). In three of
these patients, the final diagnosis was Hodgkin lymphoma
(n= 2) and pericarditis (n= 1), and in 10 patients, there
were false-positive 18F-FDG uptakes. In 20/76 patients
(26.3%), there was no pathological 18F-FDG activity.
These negative 18F-FDG PET/CT findings were more
prevalent in patients with an unknown suspected cause of
FUO before 18F-FDG PET/CT (4/5, 80.0%) compared
with suspected infection (11/37, 29.7%), malignancy (1/22,
4.5%), or NIID (5/12, 41.7%) (P= 0.004). The final diag-
nosis after 18F-FDG PET/CT was infection (n= 16),
malignancy (n= 17), NIID (n= 9), other (n= 4), and
unknown cause (n= 30). Almost 50% (n= 14) of the
patients with an unknown final diagnosis achieved spon-
taneous resolution of the fever within 3 months.
Confirmation of the suspected cause after 18F-FDG PET/
CT was possible in 59.1 und 58.3% of patients with sus-
pected malignancy and NIID, respectively. In contrast,
confirmation was only possible in 32.4% of patients with
suspected infection. Also, the rate of unknown causes of
FUO was highest among patients with suspected infection
(48.6%) and in those with an unknown suspected cause
(80.0%). As a whole, the proportion of patients with an
unknown final diagnosis increased significantly after
18F-FDG PET/CT (P< 0.001, Table 3).
The diagnostic performance of 18F-FDG PET/CT in
patients presenting with FUO irrespective of fever
quality, classified according to fever quality and the
suspected cause of FUO, is presented in Table 4. The
sensitivity of 18F-FDG PET/CT was higher in patients
with intermittent FUO compared with those with con-
tinuous FUO, and in patients with suspected malignancy
compared with those with suspected infection or NIID.
However, these differences did not reach statistical sig-
nificance (P= 0.079 and 0.082, respectively). Specificity
was low irrespective of the subgroup. In 46/76 patients
(60.5%), 18F-FDG PET/CT was considered useful in
finding the cause of FUO. Patient characteristics classi-
fied according to the success rate of 18F-FDG PET/CT
are shown in Table 5. The success rate of 18F-FDG PET/
CT was significantly higher in patients with constitu-
tional symptoms (P= 0.015) and with suspected malig-
nancy (P= 0.039). The duration and quality (intermittent
vs. continuous) of fever was comparable between
helpful and noncontributory 18F-FDG PET/CT findings.
Fig. 3
Results from a 68-year-old patient presenting with intermittent fever 4 years after aortic graft replacement. PET/CT showed vascular graft infection. (a)
Maximum intensity projection 60min after an injection of 386MBq 18F-FDG. (b) Axial slice of fused PET/CT images showing metabolically active foci
adjacent to the graft. (c) Axial slice of the corresponding CT image, showing discrete fluid collection retrosternally. CT, computed tomography;
18F-FDG, fluorine-18 fluorodeoxyglucose.
PET/CT evaluation in FUO Pereira et al. 61
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However, the success rate of 18F-FDG PET/CT with
intermittent FUO was 64% compared with 50% in
patients with continuous fever. Determinants with a
possible effect on the success rate of 18F-FDG PET/CT
in terms of the cause of FUO are shown in Table 6. In
the multivariable analysis, suspected infection was asso-
ciated negatively with the success rate of 18F-FDG PET/
CT (odds ratio 0.1, 95% confidence interval 0.01–08,
P= 0.033).
Discussion
18F-FDG PET/CT is a valuable imaging technique for
the diagnosis of infection and inflammation. Therefore,
its use has increased markedly in the last few years for the
diagnostic work-up of FUO [5,13–16]. However, there is
uncertainty in terms of the adequate timing at which an
18F-FDG PET/CT is indicated in the diagnostic work-up
of FUO. The aim of this retrospective study was to
determine the clinical usefulness of 18F-FDG PET/CT
for FUO and to define determinants of its diagnostic
performance. However, most of the studies investigating
18F-FDG PET/CT in patients with FUO are difficult to
compare because of the heterogeneity of the patient
population, differences in 18F-FDG PET/CT techni-
ques, and the stages at which it was performed.
The reported success rate and sensitivity of 18F-FDG
PET/CT in patients with FUO ranges between 33 and
75% and 72 and 100%, respectively [14,19,20,23–27].
This is in line with our own findings of a success rate of
61% and a sensitivity of 77%. The final diagnosis
Fig. 4
176 patients enrolled
76 patients included
Pathological FDG-
activity (n=56)
No pathological FDG 
activity (n=20)
Suspected diagnosis
confirmed by FDG-
PET/CT (n=43)
Suspected diagnosis
not confirmed by
FDG-PET/CT (n=13)
100 patients excluded
-  Definition of FUO not fulfilled (n=82)
-  No follow-up data (n=8)
-  Missing informed consent (n=8)
-  Incomplete data (n=2)
False-positive
FDG activity
(n=10) 1)
Infection (n=16) 2) Malignancy (n=17) 3) NIID (n=9) 4) Others (n=4) 5) Unknown (n=30)
Study flow chart. (1)Chronic anemia (n=5), hemorrhoids (n=2), recent trauma (n=2), or ankylosing spondylitis (n=1). (2)Pulmonary infection (n=4),
lymphadenitis (n=3), pericarditis (n=2), tuberculosis of the bone marrow (n=2), colitis (n=1), mycotic aortic aneurysm (n=1), liver abscess (n=1),
inguinal abscess (n=1), vascular graft infection (n=1). (3)Lymphoma (n=13), gastric cancer (n=1), lung cancer (n=1), colon cancer (n=1), thyroid
cancer (n=1). (4)Vasculitis (n=3), polymyalgia rheumatica (n=2), sacroileitis (n=1), sarcoidosis (n=1), lupus erythematosus (n=1), rheumatoid
arthritis (n=1). (5)Hemophagocytic syndrome (n=2), drug fever (n=1), common variable immune deficiency syndrome (n=1). CT, computed
tomography; 18F-FDG, fluorine-18 fluorodeoxyglucose; FUO, fever of unknown origin.
Table 2 Laboratory values before 18F-FDG PET/CT
BSR (mm/h) [mean (SD)] 66.4 (38.9)
C-reactive protein (mg/l) [median (IQR)] 83 (22–155)
Procalcitonin (ng/ml) [median (IQR)] 0.2 (0.1–1.0)
Hemoglobin (g/l) [median (IQR)] 109 (89–124)
Leukocytes (×103/μl) [median (IQR)] 7.2 (4.6–11.3)
Neutrophils (×103/μl) [median (IQR)] 4.3 (2.3–8.0)
Thrombocytes (×103/μl) [median (IQR)] 286 (173–443)
Ferritin (μg/l) [median (IQR)] 526 (213–896)
BSR, blood sedimentation rate; CT, computed tomography; 18F-FDG, fluorine-18
fluorodeoxyglucose; IQR, interquartile range.
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remained unclear in 39% of the FUO patients despite
performing an 18F-FDG PET/CT, which is within the
average range of other publications of between 34 and
46% [14,15,28]. Furthermore, in 17% of the cases,
18F-FDG PET/CT detected a cause of FUO, which had
not been suspected on the basis of preceding reasoning
and examinations including abdominal and chest CT.
Similarly, Federici et al. [18] singled out 18F-FDG PET/
CT as the only successful diagnostic tool in 23% of
patients with FUO. However, the overall diagnostic
performance of 18F-FDG PET/CT was very modest
(negative predictive value 50%, positive predictive
value 61%).
Our comparatively large study adds to previous knowl-
edge as we found that the success rate of 18F-FDG PET/
CT was associated negatively in patients with suspected
infection, but also in patients with suspected NIID
causing FUO. Perhaps, the negative impact of a sus-
pected infection or NIID on the success rate is because
of a missing focal pathological uptake of 18F-FDG in
some kind of infections or NIID (such as endocarditis
lenta, familial Mediterranean fever, or Still’s disease).
Furthermore, this could be one reason for the difference
in reported data on sensitivity as the final diagnoses in
several studies were heterogeneous. For example,
malignancy was the cause of FUO, with an incidence
Table 3 Rates of changed causes of FUO on the basis of 18F-FDG PET/CT
After 18F-FDG PET/CT
Confirmed infection Confirmed NIID Confirmed malignancy Confirmed other diagnosisa Unknown cause of FUO
Before 18F-FDG PET/CT
Suspected infection (n=37) 12 (32.4) 1 (2.7) 3 (8.1) 3 (8.1) 18 (48.6)
Suspected NIID (n=12) 1 (8.3) 7 (58.3) 0 1 (8.3) 3 (25.0)
Suspected malignancy (n=22) 3 (13.6) 1 (4.5) 13 (59.1) 0 5 (22.7)
No suspected cause of FUO (n=5) 0 0 1 (20.0) 0 4 (80.0)
Data are presented as n (%).
CT, computed tomography; 18F-FDG, fluorine-18 fluorodeoxyglucose; FUO, fever of unknown origin; NIID, noninfectious, inflammatory disease.
aOther diagnoses included central thermoregulation disorder (n=2) and adverse effect of a drug (n=2).
Table 4 Diagnostic performance of 18F-FDG PET/CT in patients with FUO irrespective of fever quality classified according to fever quality
(intermittent vs. continuous) and according to the suspected cause of FUO
Sensitivity Specificity NPV PPV LR+ LR−
All patients (n=76) 77.3 (62.2–88.5) 31.3 (16.1–50.0) 50.0 (27.2–72.8) 60.7 (46.8–73.5) 1.12 (0.9–1.5) 0.73 (0.3–1.5)
Intermittent FUO (n=56) 83.3 (67.2–93.6) 30.0 (11.9–54.3) 50.0 (21.1–78.9) 68.2 (52.4–81.4) 1.19 (0.86–1.64 0.56 (0.21–1.50
Continuous FUO (n=20) 50.0 (15.7–84.3) 33.3 (9.9–65.1) 50.0 (15.7–84.3) 33.3 (9.9–65.1) 0.75 (0.34–1.67) 1.50 (0.52–4.32)
Suspected infection (n=37) 72.2 (46.5–90.3) 31.6 (12.6–56.6) 54.5 (23.4–83.2) 50.0 (29.9–70.1) 1.06 (0.69–1.60) 0.88 (0.32–2.38)
Suspected NIID (n=12) 57.1 (18.4–90.1) 40.0 (5.3–85.3) 40.0 (5.3–85.3) 57.1 (18.4–90.1) 0.95 (0.36–2.49) 1.07 (0.27–4.23)
Suspected malignancy (n=22) 100 (79.4–100) 16.7 (0.42–64.1) 100 (2.5–100) 76.2 (52.8–91.8) 1.20 (0.84–1.72) 0.00
Values are presented in % (95% CI).
CI, confidence interval; CT, computed tomography; 18F-FDG, fluorine-18 fluorodeoxyglucose; FUO, fever of unknown origin; LR, likelihood ratio; NIID, noninfectious,
inflammatory disease; NPV, negative predictive value; PPV, positive predictive value.
Table 5 Patient characteristics classified according to the success ratea of 18F-FDG PET/CT in patients with FUO
Patient characteristics 18F-FDG PET/CT helpfula (n=46) 18F-FDG PET/CT noncontributorya (n=30) P-value
Age (years) 56.5 (15.1) 56.4 (14.6) 0.98
Male sex [n (%)] 29 (63.0) 24 (80.0) 0.12
Duration of fever (days) 134.1 (176.3) 187.6 (337.2) 0.37
Continuous FUO [n (%)] 10 (21.7) 10 (33.3) 0.26
Constitutional symptoms [n (%)] 16 (34.8) 3 (10.0) 0.015
Classical FUOb [n (%)] 29 (63.0) 27 (90.0) 0.026
C-reactive protein (mg/l) 91.6 (79.1) 112.3 (93.9) 0.31
Leukocytes (×106/l) 7.6 (4.7) 9.3 (6.4) 0.20
Previous antibiotic treatment [n (%)] 22 (56.4) 24 (64.9) 0.49
Previous immunosuppressive treatment [n (%)] 12 (30.8) 13 (35.1) 0.81
Suspected cause of FUO [n (%)] 0.039
Infection 19 (41.3) 18 (60.0)
NIID 9 (16.6) 3 (10.0)
Malignancy 17 (37.0) 5 (16.7)
Unknown 1 (2.2) 4 (13.3)
Continuous data are presented as mean (±SD) and categorical data are presented as n (%).
CT, computed tomography; 18F-FDG, fluorine-18 fluorodeoxyglucose; FUO, fever of unknown origin; NIID, noninfectious, inflammatory disease.
aThe success rate of 18F-FDG PET/CT was classified in ‘helpful’ or ‘noncontributory’ findings according to their effect on the determination of the final diagnosis (cause
of FUO).
bClassification of FUO according to Durack and Street [2].
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ranging between 3 and 20% [23,25]. In the present study,
22% of the cases were attributed to neoplasia.
The success rate of 18F-FDG PET/CT in the present
study was independent of variables such as age and sex,
as well as periodicity and duration of the fever, and
inflammatory parameters. The influence of the duration
of fever on the success rate is an inconsistent finding of
three earlier studies [14,26,28]. Whereas the diagnostic
performance of 18F-FDG PET/CT was not associated
with the duration of FUO in the prospective studies of
Bleeker-Rovers et al. [14] and Buysschaert et al. [28],
there was a significant improvement in the success rate of
18F-FDG PET/CT in patients, with a mean of 19 com-
pared with 30 days of fever in the study of Gafter-Gvili
et al. [26]. According to others [4,20,27], we support the
recommendation of performing PET/CT early in the
diagnostic work-up of FUO, albeit the duration of fever
does not seem to influence its diagnostic performance.
However, the optimal timing to perform 18F-FDG PET/
CT in patients with FUO remains to be investigated in a
future study. Presumably, the optimal timing range may
be the third week after the onset of fever, suggesting that
18F-FDG PET/CT may substitute CT of the chest and
abdomen. According to a recently proposed algorithm,
18F-FDG PET/CT should be performed after obligatory
baseline examinations including laboratory tests, chest
radiography, and abdominal ultrasonography, but before
chest and abdomen CT, which may be futile after
18F-FDG PET/CT [4]. In our study, 18F-FDG PET/CT
was performed despite a previous CT scan of the chest or
the abdomen in 60% of the cases. However, early
18F-FDG PET/CT may shorten the period of diagnostics
and disease as well as save cost in the amount of 5471
euros per patient [29] as it may avoid the need for further
futile investigations [14,15]. In our institution, the costs
of a whole-body 18F-FDG PET/CT are approximately
twice as high as the cost of a contrast-enhanced CT of the
thorax and abdomen. Moreover, early identification of
patients with malignancy may improve their outcome. As
almost 50% of the patients with an unknown cause of
FUO after 18F-FDG PET/CT achieved spontaneous
resolution of the fever, a wait-and-see period may be
indicated in these patients if the clinical situation is
stable.
Limitations
There are several limitations to the present results, which
are primarily because of the retrospective study design,
that is PET/CT scans were read by one of our experi-
enced nuclear medicine physicians (all at least with
5 years of experience in nuclear medicine in a high-
volume center with more than 5000 PET/CT examina-
tions per year); readers were not blinded to clinical
information as the examinations were part of the clinical
work-up of the patients, thus reflecting the ‘real-life-
situation’. Second, there was no set time point at which to
perform an 18F-FDG PET/CT for FUO. Thus, it was
performed on the basis of the clinician’s decision. This
may have introduced selection bias and further hetero-
geneity. Third, 18F-FDG PET/CT imaging was only
performed from the mid-thigh to the vertex of the skull;
therefore, infectious foci in the legs may have been
missed. Fourth, it is difficult to reliably determine the
diagnostic performance in patients with FUO as the
confirmation of the final diagnosis as the gold standard is
not well defined and, again, heterogeneous between
different studies. Fifth, compared with others, specificity
was low in our series, which may be because of the
heterogeneity of our study population.
Conclusion
The success rate and sensitivity of 18F-FDG PET/CT in
patients with FUO were 61 and 77%, respectively. The
success rate was associated negatively in patients with
suspected infection. However, the success rate was
independent of the duration of fever, which supports the
recommendation of performing 18F-FDG PET/CT early
in the diagnostic work-up of FUO to shorten disease
duration and lower health costs, particularly when
malignancy is suspected. However, one must keep in
mind that the cause of FUO after 18F-FDG PET/CT
remains unclear in 40% of the cases. In these patients, a
wait-and-see period may be justified. Prospective studies
investigating the precise timing and predictors of
18F-FDG PET/CT in patients with FUO need to be
designed.
Acknowledgements
Conflicts of interest
There are no conflicts of interest.
Table 6 Logistic regression analysis of possible determinants of a
helpful 18F-FDG PET/CT in patients with FUO
Univariable analysis Multivariable analysis
OR (95% CI) P-value OR (95% CI) P-value
Age 1.0 (0.9–1.1) 0.98
Sex (male) 0.4 (0.1–1.1) 0.12
Duration of fever 1.0 (0.9–1.1) 0.37
Continuous FUOa 0.6 (0.2–1.6) 0.26 0.5 (0.2–1.6) 0.28
Classical FUOb 0.0.3 (0.06–1.0) 0.13
CRP 0.9 (0.9–1.0) 0.30
Leukocytes 0.9 (0.8–1.0) 0.21
Previous antibiotic
treatment
1.4 (0.6–3.6) 0.45
Previous
immunosuppressive
treatment
1.2 (0.5–3.2) 0.69
Suspected cause of FUOa
Infection 0.1 (0.01–0.8) 0.034 0.1 (0.01–0.8) 0.033
NIID 0.3 (0.1–1.0) 0.054 0.3 (0.1–1.1) 0.068
Malignancy 0.8 (0.2–4.6) 0.88 0.9 (0.2–5.1) 0.97
CI, confidence interval; CRP, C-reactive protein; CT, computed tomography;
18F-FDG, fluorine-18 fluorodeoxyglucose; FUO, fever of unknown origin; NIID,
noninfectious, inflammatory disease; OR, odds ratio.
aIncluded in multivariable analysis.
bClassification of FUO according to Durack and Street [2].
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